By Professor Marina Pajic

Conference Abstracts

Tyma V; Liew Y-F; Tran A; Howell A; Ritchie S; Atlas AAPCM; Cox T; Pajic M; Herrmann D; Pereira B; Timpson P; Gordon K, 2024, 'Identifying and targeting FOLFIRINOX resistance mechanisms to improve outcomes in pancreatic cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, Vol. 84, presented at AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research, MA, Boston, 15 September 2024 - 18 September 2024, http://dx.doi.org/10.1158/1538-7445.PANCREATIC24-A067

Upton D; Fajardo DC; Omari S; Porazinski S; McLean B; Schuhmacher D; Istadi A; Kothari V; Finkelstein D; Machajewski T; Rock F; Turner S; Pajic M, 2024, 'Selective targeting of integrins αVβ8 and αVβ1 within the dynamic ecosystem of pancreatic cancer to improve the overall anti-tumor response', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, Vol. 84, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2024 - 10 April 2024, http://dx.doi.org/10.1158/1538-7445.AM2024-6575

Pajic M; McLean B; Fajardo DC; Porazinski S; Upton DH; Schuhmacher D; Istadi A; Cox T; Timpson P; Wilcock DJ; Anderson KJ; Mason H; Guisot NE; Jones CD; Phillips C; Armer R, 2024, 'Abstract 720: Combining zelasudil, a small molecule ROCK2 inhibitor, with chemotherapy or immunotherapy improves response in preclinical models of pancreatic cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. 720 - 720, http://dx.doi.org/10.1158/1538-7445.am2024-720

Chacon-Fajardo D; Porazinski S; Man J; Yim H; El-Omar E; Joshua A; Pajic M, 2024, 'Abstract A029: Re-purposing non-oncology agent itraconazole to target the dynamic cellular ecosystem of pancreatic cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. a029 - a029, http://dx.doi.org/10.1158/1538-7445.panca2023-a029

Porazinski S; Man J; Chacon-Fajardo D; Yim H; El-Omar E; Joshua A; Pajic M, 2024, 'Abstract C017: The anti-fungal itraconazole improves immunotherapy efficacy in pancreatic ductal adenocarcinoma by reversing the immune-suppressive tumor microenvironment', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. c017 - c017, http://dx.doi.org/10.1158/1538-7445.panca2023-c017

Pitiyarachchi O; Lin FP; Spooner A; Sharbeen G; Barker HP; Thornton K; Collignon E; Ballinger ML; Thomas DM; Magenau A; Porazinski S; Raina A; Sjoquist KM; Chantrill LA; Gebski V; Sowmya A; Timpson P; Pajic M; Goldstein D; Phillips PA, 2024, '1513P Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)', in Annals of Oncology, Elsevier, Vol. 35, pp. s925, http://dx.doi.org/10.1016/j.annonc.2024.08.1576

Murphy KJ; Reed DA; Chambers CR; Channon LM; Pajic M; Herrmann D; Timpson P, 2023, 'Anti-fibrotic FAK 'priming' to improve contemporary chemotherapy in pancreatic cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, Vol. 84, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 27 September 2023 - 30 September 2023, http://dx.doi.org/10.1158/1538-7445.PANCA2023-B037

McLean B; Fajardo DC; Istadi A; Porazinski S; Pajic M; Pajic M, 2022, 'EFFECTIVE CO-TARGETING OF FIBROTIC AND IMMUNE MICROENVIRONMENTS TO IMPROVE THE OVERALL ANTI-TUMOUR RESPONSE IN MODELS OF ADVANCED PANCREATIC CANCER', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, Vol. 10, pp. A1514 - A1514, http://dx.doi.org/10.1136/jitc-2022-SITC2022.1455

Chin VT; Nagrial A; Conway J; Vennin C; Chantrill LA; Chou A; Steinmann A; Gill AJ; Humprhis J; Drury A; Froio D; Morgan A; Biankin A; Timpson P; Pajic M, 2017, 'Effect of Rho/ROCK pathway inhibition on metastasis-free and overall survival in biomarker selected, orthotopic, patient-derived models of pancreatic cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, pp. e15759 - e15759, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15759

Chin VT; Conway J; Nagrial A; Chantrill LA; Chou A; Steinmann A; Gill A; Pinese M; Wu J; Johns A; Dury A; Biankin A; Timpson P; Pajic M, 2015, 'Targeting the Rho-ROCK pathway to treat pancreatic cancer: The use of unique preclinical models to ascertain the effects on cancer growth and metastasis', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 33, presented at Gastrointestinal Cancers Symposium, CA, San Francisco, 15 January 2015 - 17 January 2015, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.312

Chin VT; Nagrial A; Chantrill LA; Chang DK; Chou A; Humprhis J; Cowley M; Wu J; DiPetro R; Watson C; Spielman C; Steinmann A; Pinese M; Pettitt J; Johns A; Waddell N; Grimmond S; Timpson P; Biankin AV; Pajic M, 2013, 'From functional genomics to precision medicine: The therapeutic potential of targeting ROCK signaling in pancreatic cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 31, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419603693&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Humphris J; Johns A; Simpson S; Chang D; Cowley MJ; Pajic M; Jones M; Simpson S; Mead S; Biankin A, 2012, 'Risk factors for pancreatic cancer in patients with and without a family history of pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, Vol. 27, pp. 127 - 127, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308642600262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pajic M; Chang DK; Kassahn KS; Wu J; Cowley M; Waddell N; Johns A; Grimmond SM; Biankin AV, 2012, 'Proffered Paper: Testing Individualised Treatment Strategies in Preclinical Models of Pancreatic Cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, Barcelona, Vol. 48, pp. S22 - S22, presented at 22nd Biennial Congress of the European-Association-for-Cancer-Research, SPAIN, Barcelona, 07 July 2012 - 10 July 2012, http://dx.doi.org/10.1016/S0959-8049(12)70795-5

Murray J; Burkhart CA; Watt F; Pajic M; Flemming C; Smith J; Gudkov AV; Haber M; Norris MD, 2006, '169 POSTER Sensitisation of neuroblastoma tumours to chemotherapy by use of a novel class of MRP1 small molecule inhibitor', in European Journal of Cancer Supplements, Elsevier, Vol. 4, pp. 54, http://dx.doi.org/10.1016/s1359-6349(06)70175-6

Working Papers

Thejer BM; Adhikary PP; Kaur A; Teakel SL; Oosterum AV; Seth I; Pajic M; Hannan KM; Pavy M; Poh P; Jazayeri JA; Zaw T; Pascovici D; Ludescher M; Pawlak M; Cassano JC; Turnbull L; Jazayeri M; James AC; Coorey CP; Roberts TL; Kinder SJ; Hannan RD; Patrick E; Molloy MP; J. E; Fehm TN; Neubauer H; Goldys EM; Weston LA; CAHILL M, PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth, Research Square Platform, http://dx.doi.org10.21203/rs.2.22342/v3

Thejer BM; Adhikary PP; Kaur A; Teakel SL; Van Oosterum A; Seth I; Pajic M; Hannan KM; Pavy M; Poh P; Jazayeri JA; Zaw T; Pascovici D; Ludescher M; Pawlak M; Cassano JC; Turnbull L; Jazayeri M; James AC; Coorey CP; Roberts TL; Kinder SJ; Hannan RD; Patrick E; Molloy MP; New EJ; Fehm TN; Neubauer H; Goldys EM; Weston LA; Cahill MA, PGRMC1 phosphorylation and cell plasticity 1: glycolysis, mitochondria, tumor growth, Cold Spring Harbor Laboratory, http://dx.doi.org10.1101/737718

Preprints

Brunton H; Caligiuri G; Cunningham R; Upstill-Goddard R; Bailey U-M; Garner IM; Nourse C; Dreyer S; Jones M; Moran-Jones K; Wright DW; Paulus-Hock V; Nixon C; Thomson G; Jamieson N; McGregor GA; Evers L; McKay CJ; Gulati A; Brough R; Bajrami I; Pettit S; Dziubinski ML; Barry ST; Grützmann R; Brown R; Curry E; Laboratory GPO; Initiative APCG; Pajic M; Musgrove EA; Petersen G; Shanks E; Ashworth A; Crawford HC; Simeone DM; Froeling FEM; Lord CJ; Mukhopadhyay D; Pilarsky C; Grimmond SE; Morton JP; Sansom OJ; Chang DK; Bailey P; Biankin AV, 2019, HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer, http://dx.doi.org/10.2139/ssrn.3430714

Wang K; Huynh N; Wang X; Pajic M; Parkin A; Man J; Baldwin G; He H; Nikfarjam M, 2018, The PAK Inhibitor PF-3758309 Promotes the Inhibitory Effects of Multiple Chemotherapeutic Reagents on Patient-Derived Pancreatic Cancer Cell Lines, http://dx.doi.org/10.20944/preprints201809.0322.v1

Colino-Sanguino Y; de la Fuente LR; Gloss B; Law AMK; Handler K; Pajic M; Salomon R; Gallego-Ortega D; Valdes-Mora F, Performance comparison of high throughput single-cell RNA-Seq platforms in complex tissues, http://dx.doi.org/10.1101/2023.04.04.535585

Thejer BM; Adhikary PP; Kaur A; Teakel SL; Oosterum AV; Seth I; Pajic M; Hannan KM; Pavy M; Poh P; Jazayeri JA; Zaw T; Pascovici D; Ludescher M; Pawlak M; Cassano JC; Turnbull L; Jazayeri M; James AC; Coorey CP; Roberts TL; Kinder SJ; Hannan RD; Patrick E; Molloy MP; J. E; Fehm TN; Neubauer H; Goldys EM; Weston LA; CAHILL M, PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth, http://dx.doi.org/10.21203/rs.2.22342/v1

Thejer BM; Adhikary PP; Kaur A; Teakel SL; Oosterum AV; Seth I; Pajic M; Hannan KM; Pavy M; Poh P; Jazayeri JA; Zaw T; Pascovici D; Ludescher M; Pawlak M; Cassano JC; Turnbull L; Jazayeri M; James AC; Coorey CP; Roberts TL; Kinder SJ; Hannan RD; Patrick E; Molloy MP; J. E; Fehm TN; Neubauer H; Goldys EM; Weston LA; CAHILL M, PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth, http://dx.doi.org/10.21203/rs.2.22342/v2

Murphy KJ; Chambers CR; Reed DA; Channon LM; Mills NE; McKay SE; Lee V; Howell AE; Tran AM; Nobis M; Magenau A; Stoehr J; Pereira BA; Kuepper N; Ritchie S; Gordon K; Trpceski M; Tyma VM; Hafiz S; Johri V; Ang A; Barkauskas DS; Vennin C; Wang XQ; Naeini MM; Meyer B; Parker AL; Gummadi S; Chitti SV; Fajardo DC; Zaratzian A; Tayao M; Da Silva A; Initiative APG; Atlas APM; Cesare AJ; Mathivanan S; Stirzaker C; Latham SL; Croucher DR; Sharbeen G; Phillips PA; Goldstein LD; Lyons RJ; Nagrial A; Pavlakis N; Gill AJ; Biankin AV; Samra J; Caldon CE; Evans TRJ; Chantrill L; Horvath LG; Sansom OJ; Morton JP; Phan TG; Wang Y; Cock T-A; Kinkel SA; Bishop A; Devlin M; Lambert J; Cox TR; Pajic M; Burns CJ; Herrmann D; Timpson P, Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer, http://dx.doi.org/10.64898/2026.07.23.740234

Kryza T; Khan T; Lovell S; Harrington BS; Yin J; Porazinski S; Pajic M; Koistinen H; Rantala J; Dreyer T; Magdolen V; Reuning U; He Y; Tate E; Hooper JD, Substrate-biased activity-based probes identify the urokinase-plasminogen axis as a master regulator of metastatic signaling by orphan membrane receptor CDCP1, http://dx.doi.org/10.21203/rs.3.rs-92391/v1

Dreyer SB; Upstill-Goddard R; Paulus-Hock V; Paris C; Lampraki E-M; Dray E; Serrels B; Caligiuri G; Rebus S; Brunton H; Cunningham R; Nourse C; Bailey U-M; Jones M; Moran-Jones K; Wright DW; Duthie F; Oien K; Evers L; McKay CJ; McGregor GA; Gulati A; Brough R; Bajrami I; Pettitt S; Dziubinski ML; Candido J; Balkwill F; Barry ST; Grützmann R; Rahib L; Laboratory GPO; Initiative APCG; Johns A; Pajic M; Froeling FEM; Beer P; Musgrove EA; Petersen GM; Ashworth A; Frame MC; Crawford HC; Simeone DM; Lord C; Mukhopadhyay D; Pilarsky C; Cooke SL; Jamieson NB; Morton JP; Sansom OJ; Bailey PJ; Biankin AV; Chang DK, Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer, http://dx.doi.org/10.1101/713545

Kokkinos J; Sharbeen G; Ignacio RMC; Pandzic E; Youkhana J; Boyer C; Haghighi KS; Gunawarman M; Goldstein D; Gebski V; Pajic M; Pitiyarachchi O; Davis ME; Schulstad G; Arkell OSM; Kopecky C; Gonzales-Aloy E; Erkan M; Morton JP; Kavallaris M; Gunning PW; Hardeman EC; Johns A; Gill AJ; Whan RM; Mawson A; Initiative APCG; McCarroll JA; Phillips PA, βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer, http://dx.doi.org/10.1101/2022.09.29.510034

Other

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Data from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.c.8179124

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761555

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761552

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S3 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761549

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761546

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761543

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761540

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761537

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S10 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761534

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S11 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761531

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761528

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S3 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761525

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761522

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761519

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761516

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S7 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761513

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S8 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761510

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S9 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761507

Back to profile page